Loading...
Market
What will be the primary challenge in Neuralink's Canadian trials by end of 2025?
2
Resolution / Starting Odds
Regulatory issues • 25%
Technical failures • 25%
Patient recruitment difficulties • 25%
No major challenges • 25%
Reports from Neuralink or Health Canada regarding trial progress
Story
Neuralink Receives Approval for First Canadian Clinical Trial at Toronto Western Hospital
Nov 21, 2024, 10:30 AM
Neuralink, the neurotechnology company founded by Elon Musk, has received approval from Health Canada to begin recruitment for its first clinical trial in the country. The trial, part of the CAN-PRIME study, will be conducted at Toronto Western Hospital, marking the first non-U.S. site for Neuralink's brain implant tests. The study aims to assess the safety and initial functionality of the N1 chip, a wireless brain implant designed to allow paralyzed individuals to control digital devices using their thoughts. Recruitment is now open for quadriplegia patients, expanding on Neuralink's existing U.S. trials.
View original story
Similar markets
Recruitment completion • 25%
Initial results published • 25%
Trial expansion approved • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
Collaboration with a Canadian university • 25%
Partnership with a Canadian healthcare provider • 25%
Partnership with a tech company • 25%
No major partnership • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive outcome • 25%
Trial not completed • 25%
New safety guidelines • 25%
Faster approval processes for BCI • 25%
Stricter regulations • 25%
No regulatory changes • 25%